432 related articles for article (PubMed ID: 28382569)
1. Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies.
Moreira J; Tobias A; O'Brien MP; Agulnik M
Drugs; 2017 May; 77(8):843-857. PubMed ID: 28382569
[TBL] [Abstract][Full Text] [Related]
2. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.
Bhatia A; Burtness B
Drugs; 2023 Feb; 83(3):217-248. PubMed ID: 36645621
[TBL] [Abstract][Full Text] [Related]
3. An update: emerging drugs to treat squamous cell carcinomas of the head and neck.
Lee YS; Johnson DE; Grandis JR
Expert Opin Emerg Drugs; 2018 Dec; 23(4):283-299. PubMed ID: 30376740
[No Abstract] [Full Text] [Related]
4. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.
Mehra R; Cohen RB; Burtness BA
Clin Adv Hematol Oncol; 2008 Oct; 6(10):742-50. PubMed ID: 18997665
[TBL] [Abstract][Full Text] [Related]
5. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
Bozec A; Peyrade F; Milano G
Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
[TBL] [Abstract][Full Text] [Related]
6. Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond.
Harari PM; Wheeler DL; Grandis JR
Semin Radiat Oncol; 2009 Jan; 19(1):63-8. PubMed ID: 19028347
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck.
Sharafinski ME; Ferris RL; Ferrone S; Grandis JR
Head Neck; 2010 Oct; 32(10):1412-21. PubMed ID: 20848399
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
9. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
10. Current Role of Dacomitinib in Head and Neck Cancer.
Elicin O; Ozsahin M
Expert Opin Investig Drugs; 2016 Jun; 25(6):735-42. PubMed ID: 27070370
[TBL] [Abstract][Full Text] [Related]
11. Targeted Therapy of Head and Neck Cancer.
Rieke DT; Klinghammer K; Keilholz U
Oncol Res Treat; 2016; 39(12):780-786. PubMed ID: 27889751
[TBL] [Abstract][Full Text] [Related]
12. HER2 as a therapeutic target in head and neck squamous cell carcinoma.
Pollock NI; Grandis JR
Clin Cancer Res; 2015 Feb; 21(3):526-33. PubMed ID: 25424855
[TBL] [Abstract][Full Text] [Related]
13. Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma.
Devaraja K
Pharmaceut Med; 2019 Aug; 33(4):269-289. PubMed ID: 31933185
[TBL] [Abstract][Full Text] [Related]
14. Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer.
Bauman JE; Ferris RL
Cancer; 2014 Mar; 120(5):624-32. PubMed ID: 24222079
[TBL] [Abstract][Full Text] [Related]
15. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
Machiels JP; Schmitz S
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
[TBL] [Abstract][Full Text] [Related]
16. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
Pogorzelski M; Ting S; Gauler TC; Breitenbuecher F; Vossebein I; Hoffarth S; Markowetz J; Lang S; Bergmann C; Brandau S; Jawad JA; Schmid KW; Schuler M; Kasper S
Cell Death Dis; 2014 Feb; 5(2):e1091. PubMed ID: 24577089
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.
Rothschild U; Muller L; Lechner A; Schlösser HA; Beutner D; Läubli H; Zippelius A; Rothschild SI
Swiss Med Wkly; 2018; 148():w14625. PubMed ID: 29756633
[TBL] [Abstract][Full Text] [Related]
18. Afatinib in the treatment of head and neck squamous cell carcinoma.
Ferrarotto R; Gold KA
Expert Opin Investig Drugs; 2014 Jan; 23(1):135-43. PubMed ID: 24266694
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
20. EGFR-targeting monoclonal antibodies in head and neck cancer.
Astsaturov I; Cohen RB; Harari PM
Curr Cancer Drug Targets; 2006 Dec; 6(8):691-710. PubMed ID: 17168674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]